Lilly reports retatrutide and Taltz-Zepbound data ahead of ACR Convergence
Eli Lilly will present new clinical data at the American College of Rheumatology Convergence 2026, held Nov. 6-11, on retatrutide in knee osteoarthritis with obesity and on Taltz plus Zepbound in psoriatic arthritis with obesity. In TRIUMPH-4, retatrutide cut WOMAC knee pain by up to 4.5 points, or 75.8%, from a 6.0 baseline, with more than 1 out of 8 treated patients reporting no knee pain at trial end. In the 52-week TOGETHER-PsA study, ACR50 achievement was 43.7% with the combination versus 15.7% with Taltz monotherapy.
Why it matters
The readouts provide clinical evidence for Lilly's investigational retatrutide and for combining its marketed Taltz and Zepbound in patients with obesity-related rheumatologic disease. Retatrutide remains investigational, so the event reports trial findings rather than a regulatory approval or a change in product status.
Key facts
- 1Lilly's presentations are scheduled for the American College of Rheumatology Convergence 2026 in Orlando from Nov. 6-11, 2026. prnewswire.com
- 2In the 68-week TRIUMPH-4 trial, retatrutide reduced WOMAC knee osteoarthritis pain by up to 4.5 points, or 75.8%, from a 6.0 baseline, and more than 1 out of 8 treated patients had no knee pain at the end. prnewswire.com
- 3In the 80-week TRIUMPH-1 trial, retatrutide reduced WOMAC knee osteoarthritis pain by up to 4.3 points, or 73.1%, from a 6.0 baseline, and more than 1 out of 6 treated patients had no knee pain at the end. prnewswire.com
- 4At 52 weeks in TOGETHER-PsA, ACR50 attainment was 43.7% with Taltz plus Zepbound versus 15.7% with Taltz monotherapy. prnewswire.com
- 5Retatrutide is an investigational once-weekly GIP, GLP-1 and glucagon triple hormone receptor agonist. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.